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Background: In this study we compare the outcomes of the paclitaxel-eluting stent
(PES) versus the everolimus-eluting stent (EES) treated patients at a tertiary medical
center and up to two years follow up.
Methods: Unselected consecutive patients were retrospectively recruited following
stenting with PES (159 patients) or EES (189 patients). The first 100 consecutive patients
in each cohort underwent syntax scoring. The primary endpoint of the study was target
lesion failure (TLF) defined as the combined endpoint of cardiac death, non fatal myocardial
infarction or target lesion revascularization (TLR). Secondary endpoints included target vessel
revascularization (TVR), target lesion revascularization (TLR), target vessel failure (TVF),
acute stent thrombosis (ST), total death, cardiac death, and non fatal myocardial infarction
(MI). Analysis was performed with patient number as the denominator.
Results: The syntax scores in the 2 groups were similar (20.3  13.9 vs 20.4  13.8,
p0.97). Patients treated with the PES stent had less congestive heart failure and
restenotic lesions, but a higher prevalence of longer lesions, non left main bifurcations, and
required more stents per patient (4.3  2.8 vs. 2.9  2.1). The primary unadjusted
outcome of TLF occurred in 29.3% PES vs 20.3% EES (p0.059). The secondary
unadjusted endpoints for PES vs EES respectively were: TVF 36.7% vs 28.0% (p0.106),
TVR 35.7% vs 26.5% (p0.079), definite and probable ST 1.2% vs 1.6%, non fatal MI
4.5% vs. 4.2%, and cardiac mortality 5.6% vs 3.2%. A propensity matched analysis showed
no significant difference in the primary endpoint of TLF (28.6%  16 vs 24.6%  14,
p0.67) in PES vs EES respectively.
Conclusion: Using unadjusted analysis, EES had lower TLF than PES in a broad cohort
of patients and lesions undergoing PCI. However, when baseline differences between the
2 cohorts were adjusted for, similar efficacy between the PES and EES was seen at 2 years
follow-up.
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Background: Small vessel diameter is associated with increased restenosis rates and
adverse outcomes following coronary stenting. The PLATINUM Japan Small Vessel
multicenter study specifically assessed small vessel stenting in Japanese patients treated
with the PROMUS Element everolimus-eluting stent (Boston Scientific, Natick, MA).
Follow-up beyond 1 year has not been reported previously.
Methods: Patients with a single de novo target lesion28 mm long and2.25 to2.50
mm in diameter were eligible for treatment with a 2.25 mm diameter PROMUS Element
stent.
Results: A total of 60 patients were enrolled at 14 clinical sites; 32 patients were
randomized to receive routine angiography following the 1-year clinical follow-up
(angiography was completed in 29 patients). Patients were 69.29.8 years of age, 68.3%
male, and 36.7% had medically treated diabetes. Average baseline reference vessel
diameter was 2.020.26 mm. Technical success and procedural success were both 100%
(60/60). Post-dilation was used in 70.0% with a 16.6 atm average pressure. Dual
antiplatelet treatment was used in 78.3% of patients at 2 years post-procedure. Two-year
clinical follow-up is complete in 100% of patients. Through 365 days post-procedure,
there were no major adverse cardiac events. In-stent late loss was 0.180.30 mm in the
angiographic subset. Following angiographic assessments (366-396 days post-procedure)
target lesion revascularization (TLR) occurred in 2 patients (including 1 patient in the
angiographic subset); there were no additional TLRs through the 2-year follow-up.
Target vessel revascularization outside the target lesion occurred in 3 patients through the
2-year follow-up. One patient (1.7%) experienced a non-Q-wave myocardial infarction
(MI) in the target vessel 413 days post-procedure. There were no Q-wave MIs or stent
thromboses through 2 years.
Conclusion: The results support the safety and efficacy of the PROMUS Element 2.25
mm stent in Japanese patients.
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Drug Eluting Balloon for De-Novo, In stent Restenosis and Bifurcation Lesions of
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Objectives: This prospective study designed to assess the safety and short and
intermediate term efficacy of drug eluting balloon (DEB) in the treatment of de-novo,
in-stent restenosis and bifurcation coronary artery disease (CAD) in Saudi Arabic
Population.
Methods: Total of 64 patients so far enrolled in a prospective registry using a Be Brown
Paclitaxel-coated balloon (DEB) at our hospital, 61 patients were studied for short and
intermediate term outcomes (6 to 12 months). All patients with symptomatic CAD
requiring percutaneous intervention (PCI) with DEB were included. Clinical follow-up
was conducted at 6 to 12 months. Coronary angiography (CAG) or SPECT Scan were
done in 70% of patients during this period. Primary outcome was a composite of target
vessel revascularization and mortality.
Results: Procedural success was achieved in 96% of the patients. Two patients were
failed due to failed DEB to cross heavily calcified vessel. Mean age was 60.830 years. 47
patients (77%) presented with stable angina and 9 patients 15% with acute coronary
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